Overview

Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma

Status:
RECRUITING
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
Based on different subtypes, subjects will be placed in one of three treatment groups to explore individual efficacy and safety of various treatment regimen.
Phase:
PHASE2
Details
Lead Sponsor:
Fudan University
Treatments:
anlotinib
Everolimus
tislelizumab